Duvelisib cream for early-stage mycosis fungoides
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a cream containing duvelisib, a drug that may help treat the skin patches of early-stage mycosis fungoides, a type of skin lymphoma. The cream is applied directly to the affected skin to see if it can control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage IA, IB, or IIA mycosis fungoides (the early form of this skin lymphoma).
- You need to have 3 to 5 active skin lesions that can be reached with the cream, but not on your face, neck, groin, or buttocks.
- Your lymph nodes must not be significantly enlarged (under 1.5 centimeters).
- You cannot have had certain treatments like other PI3K inhibitors within the past 60 days, or topical steroids on the lesions within the past 2 weeks (a 14-day break may allow you to join).
- You cannot have had systemic treatments for mycosis fungoides (like steroids, light therapy, or chemotherapy) within the past 3 weeks, or electron beam radiation within the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cream applied to the skin that may help control early-stage mycosis fungoides, a type of skin lymphoma. It aims to see if the cream can reduce symptoms and slow disease progression without the need for stronger treatments.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
This study tests a cream called benvitimod to see if it helps treat cutaneous T-cell lymphoma, a type of skin lymphoma. It is for adults who have already been diagnosed with this condition.
This early-stage study tests whether a cancer-killing cream (imiquimod) combined with targeted local radiation can shrink and control mycosis fungoides skin lesions. It may help people whose skin lymphoma has not responded to at least one prior standard treatment.
This early-phase study tests a spray solution (APR-TD011®) for people with early-stage mycosis fungoides and looks at how the bacteria on the skin change before and after treatment. It may help researchers understand whether the spray improves the skin environment that can affect this lymphoma.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
Hear when a new Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.